CoChat
Sign Up
Cited by 54Cancer Treatment and PharmacologyBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer

Acuña, L. Romero, Langhi, M., Pérez, J., Acuña, J. Romero, Machiavelli, M., Lacava, J., Vallejo, C., Romero, A. +7 more·1999·Journal of Clinical Oncology
DOI 10.1200/jco.1999.17.1.74
Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and toxicity of a combination of vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy in metastatic breast carcinoma (MBC). PATIENTS AND METHODS: Between August 1995 and August 1997, 49 patients with untreated MBC received a regimen that consisted of VNB 30 mg/m 2 in a 20-minute intravenous (IV) infusion on days 1 and 8 and PTX 135 mg/m 2 in a 3-hour IV infusion (starting 1 hour after VNB) on day 1. Cycles were repeated every 28 days. The median age of the patients was 52 years, and 59% of patients were postmenopausal. Median performance status was 1. Dominant sites of disease were soft tissue in 6%, bone in 29%, and viscera in 65%. RESULTS: Objective responses were recorded in 27 of 45 assessable patients (60%; 95% confidence interval, 46% to 74%). Complete remissions occurred in three patients (7%), and partial remissions occurred in 24 patients (53%). No change was recorded in 12 patients (27%), and progressive disease occurred in six patients (13%). The median time to treatment failure was 7 months, and median survival duration was 17 months. The limiting toxicity was myelosuppression, mainly leukopenia in 49 patients (100%) (grade 1 to grade 2, four patients; grade 3, 30 patients; and grade 4, 15 patients). Neutropenia was observed in 100% of patients (grade 1 to grade 2, three patients; grade 3, 11 patients; grade 4, 35 patients). Two treatment-related deaths due to febrile neutropenia were observed in patients with massive liver involvement. Peripheral neurotoxicity developed in 33 patients (67%) (grade 1, 25 patients; grade 2, eight patients); there were no grade 3 or grade 4 episodes. CONCLUSION: The combination of VNB-PTX showed significant activity as first-line chemotherapy for patients with MBC. Myelosuppression was the dose-limiting side effect, whereas neurotoxicity was mild to moderate.

Integrity signals

Registry

Crossref · 10.1200/jco.1999.17.1.74

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Acuña, L. R., Langhi, M., Pérez, J., Acuña, J. R., Machiavelli, M., Lacava, J., Vallejo, C., Romero, A., Fasce, H., Ortiz, E., Grasso, S., Amato, S., Rodríguez, R., Barbieri, M., & Leone, B.
Affiliations
From the Grupo Oncológico Cooperativo del Sur, Argentina.
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
1999-01
Volume
17
Issue
1
Pages
74-74
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.1999.17.1.74
OpenAlex
W1949548665
Cited by
54
References
35
Citations by year
2021: 1 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 1 · 2012: 1
FWCI
3.17
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
Keywords
vinorelbine, paclitaxel, metastatic breast cancer, first-line chemotherapy, combination chemotherapy, myelosuppression, neutropenia, peripheral neurotoxicity, treatment toxicity, objective response rate, survival
MeSH terms
Vinorelbine, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Metastasis, Prospective Studies, Vinblastine, Survival Rate, Paclitaxel, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review